Is Injective Protocol (INJ) soaring on mainnet launch news?

July 07, 2022 06:46 PM IST | By Rupam Roy
 Is Injective Protocol (INJ) soaring on mainnet launch news?
Image source: © Kviztln | Megapixl.com

Highlights:

  • The Injective Protocol announced that its mainnet upgrade went live on July 5.
  • The INJ token trades on exchanges like Bilaxy, Huobi Global, etc.
  • It returned over 9% gains in the last seven days.

The Injective Protocol (INJ) crypto gained significant traction after the smart contracts went live on the platform following its mainnet upgrade. Its price was up more than 2% in the last 24 hours. However, its one-day volume declined by over 52% in the same period.

What is Injective Protocol (INJ) crypto?

Injective Protocol offers limitless access to decentralized finance markets. The users could build any financial market on the Injective's decentralized exchange protocol. It claims its exchange protocol is fully decentralized, secured, fast, cross-chain, and has zero-gas fees.

The platform is custom-built for supporting Ethereum-compatible decentralized finance (DeFi) apps that reach instant finality, with 2-second block times and a speed of 10,000 transactions per second (TPS). Injective's trading infrastructure is backed by a central limit order book, with a user-friendly interface and decentralized exchange features.

Its unique decentralized protocol supports cross-chain trading of cryptos, futures, and other assets across different blockchains like Ethereum, BSC, etc.

INJ is the native token of the platform used in governance, exchange value capture, liquidity mining, and staking. It traded on crypto exchanges like Bilaxy, Huobi Global, Uniswap, etc.

Meanwhile, Injective announced that its Injective CosmWasm Smart Contract Layer or Mainnet upgrade went live on July 5. After the upgrade, features like self-executing smart contracts, binary options, interchain accounts, etc., were introduced on the platform.

Injective said that its upgrade proposal was approved by over 99.50% of its community members. The CosmWasm Mainnet Upgrade or Injective Canonical 1006-rc1 has added various improvements for project developers.

Injective Protocol (INJ) crypto price and performanceData Source: CoinMarketCap.com

Bottom line:

The INJ crypto was priced at US$1.29 at 8:17 am ET on July 7, up 2.23%, while its trading volume for the trailing 24 hours fell 52.57% to US$10.17 million. It has a market cap of US$83.99 million, and its fully-diluted market cap is US$129.20 million.

The token has a maximum and total supply of 100 million, and its current circulating supply is more than 65.00 million. It returned gains of 9.19% in the last seven days.

The INJ token saw the highest price of US$2.32 and the lowest price of US$1.14 in the last 30 days.

Risk Disclosure: Trading in cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory, or political events. The laws that apply to crypto products (and how a particular crypto product is regulated) may change. Before deciding to trade in financial instruments or cryptocurrencies you should be fully informed of the risks and costs associated with trading in the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Kalkine Media cannot and does not represent or guarantee that any of the information/data available here is accurate, reliable, current, complete, or appropriate for your needs. Kalkine Media will not accept liability for any loss or damage as a result of your trading or your reliance on the information shared on this website.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.